TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under The Concentration Curve From Time 0 to 12 Hours (AUC(0-12))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) for Responding Patients
Endpoint domain: Mortality/survival
Primary endpoint: Sliding Dichotomy modified Rankin Scale (mRS) at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Serious Adverse Events From Dose 1 to 1 Month After Dose 4
Endpoint domain: Adverse events/effects
Primary endpoint: sustained effectiveness of IV forodesine hydrochloride infusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Defibrillation Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: electrical activity of the anterior tibial muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased levels of ubiquitin proteasome pathway proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants with severe illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants with omphalitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Concentration and/or activity of IGF-I in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration and/or activity of IGF-II in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of NGF in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concentration of BDNF in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concentration of sCD163 in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attendance at colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of serum total bilirubin (TB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Proportion of Participants With Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of healed blistering distal dactylitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change In Diastolic Blood Pressure From Baseline To Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Ears Experiencing an Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Ears With Successful Delivery of the Tympanostomy Tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Successful Completion of Procedure In-office
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete resolution of pleural effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival of patients with metastatic breast cancer in Austria
Endpoint domain: Mortality/survival
Primary endpoint: RBC transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: erythroid response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence rate of deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximally tolerated dose of OPT-821
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-NB activity of the bivalent vaccine plus oral β-glucan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adjuvant effect of oral beta-glucan on anti-GD2 antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with heterogenous myocardial conduction features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation with ventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Participants Surviving With a Functioning Graft by Month 12
Endpoint domain: Mortality/survival
Primary endpoint: Percent of Participants With a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12 or With a Decrease in mGFR Greater Than or Equal to 10 mL/Min/1.73m^2 From Month 3 to Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent of Participants Experiencing Acute Rejection (AR) Post-transplant by Month 12
Endpoint domain: Adverse events/effects
Primary endpoint: Tapering off of psychoactive medication
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cessation of Viral Shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prescription for any beta-blocker
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Venous Nicotine Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak torsemide plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total torsemide plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to receive treatment from exacerbation onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CKMB and Troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline of Immune Cell Populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Cell Surface Antigen Phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Withdrawal from allocated treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PK exposure determined from plasma concentration versus time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: control rate of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker faces pain rating scale (WBFPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant's future preference
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Finger Fractionation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge Retention of Warfarin Education
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraoperative thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of inappropriate insertion of nasotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of cardiovascular comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive and negative predictive values for the diagnosis of active TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of AAD
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary and fecal recoveries of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: OASIS Wellness and Disease Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short Form, 36 question form
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Withings Heartrate & Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous miscarriage
Endpoint domain: Mortality/survival
Primary endpoint: Medically Attended Skin and Soft Tissue Infections (MA-SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Chylomicron transport rate and magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in the Total Motor Score (TMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Opioid Consumption (Morphine Equivalent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Estimating blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time To Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Bleeding Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Numeric Rating Scale Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OR and PACU Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean P-selectine expression in all platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean CD63 expression in all platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean CD40 Expression in all platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean platelet-monocyte-conjugate formation in the monocyte population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of 5Ve isopter Goldmann visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression to neovascular glaucoma requiring pan-retinal photocoagulation or glaucoma surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation to visual food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants perception of the headgear on mask performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Foot deformity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment using Visual Analog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Medication Requirement, mg in IV Morphine Equivalent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of stool passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bacterial culture for intestinal or cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance assessed using Psychomotor vigilance task (PVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance assessed using Sustained Attention to Response Task (SART)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance assessed using Digit Symbol Substitution Test (DSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complication rate (including death)
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time at Which Cmax is Attained (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Blood Conc. Versus Time Curve (AUC(0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in 68Ga-PSMA-11 lesion and total-body uptake (SUVmax and SUVmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Remission at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergen-specific biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Bacteroidetes to Firmicuites ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fuss-cry behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Alprazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SLE disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urgency (ESM score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urgency (SR-BD score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of composite endpoint (death, reinfarction, new revascularization, rehospitalization, severe hemorrhage)
Endpoint domain: Mortality/survival
Primary endpoint: Procedural and technical success - operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in residual volume > 300mL from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial flow in Common Carotid Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial flow in Internal Carotid Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial flow in External Carotid Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial flow in Vertebral Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in post-concussion symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in post-concussion symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in post-concussion symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Working Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Opiate Related Symptom Distress Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Object response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrence rates of vivax malarial infection
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
Endpoint domain: Adverse events/effects
Primary endpoint: clinical pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: 5-years overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Myocardial Viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stimulation index of 3 or greater to tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: positive serologic response to hepatitis A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: four-fold increase in antibody titers for tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of GSK2256098
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of GSK2256098
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nursing home utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Trail Making Tests (Parts A & B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Timed Up and Go Test Dual Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in hscTnI Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease Activity Score (DAS) 28 on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score (DAS) 28 on Day 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer assessment scale- lower extremity (FMA-LE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinetti gait and balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical darkening of striaes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quit attempt
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: safety of continued dosing with ALX1-11
Endpoint domain: Adverse events/effects
Primary endpoint: subjective memory changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Opioid Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: haemodynamic values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of topical sodium nitrite cream
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of confirmed tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: pH readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Renal oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Coronary collateral resistance (Rcoll)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall improvement in GMFM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful reversal of global cerebral vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Readmission due to Atrial Fibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: Peak thrombin Generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Rankin Scale (MRS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: absolute bioavailability (F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Profilometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between lactate values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated red blood cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Confirmed disease progression in patients with EDSS ≤2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Confirmed disease progression in patients with EDSS ≥2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Disease-related impact on daily life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DNA damage and apoptosis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure sensitivity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal cord dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects with leg wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumor activity (response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Shrinkage profiles of the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste preference of oral solution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression to IMV and/or ECMO or Death
Endpoint domain: Mortality/survival